Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13673576 | 0.85 | SMN1; SMN2 (0.60) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL23996059 | 0.85 | SMN1; SMN2 (0.60) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL7747519 | 0.85 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL7747517 | 0.85 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL13673610 | 0.84 | KDM4E (0.50) | MAPTKDM4EALDH1A1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL915893 | 0.84 | MAPT (0.55) | MAPTKDM4EALDH1A1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL915892 | 0.84 | MAPT (0.55) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL15365567 | 0.81 | KDM4E (0.72) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL1157558 | 0.80 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AGAA | |
| SCHEMBL1157559 | 0.80 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410174-B2 | Method for treating arthritis | ANAMAR AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-8309609-B2 | Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands | ANAMAR AB (SE) | 2012-11-13 | — | — | US | disclosed |
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | ANA-MAR AB (SE) | 2012-07-26 | — | — | US | disclosed |
| EP-2470270-A1 | COMPOUNDS FOR TREATMENT OF INFLAMMATION | AnaMar AB (SE) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011012868-A1 | COMPOUNDS FOR TREATMENT OF INFLAMMATION | ANAMAR AB (SE) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190751-A1 | COMPOUNDS FOR TREATMENTS OF INFLAMMATION | IL6, IL1B, TNF | MAPT 3564/4885KDM4E 597/4885ALDH1A1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.